Silence Therapeutics PLC – Collaboration with Genomics England

Silence Therapeutics PLC – Collaboration with Genomics England

Silence Therapeutics, PLC (LON: SLN)a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has entered into a collaboration with Genomics England Limited for the investigation of novel targets involved in human disease.

Genomics England has generated a unique database of over 100,000 human genomes, for which whole genome sequencing data has been linked with clinical data. This database is a powerful resource for Silence, given its ability to specifically silence disease-associated genes.  

Under the terms of the agreement, Silence has been approved for access to a subset of Genomics England’s dataset as the Company plans to focus its research on rare disease and cardiometabolic cohorts. Silence will now proceed to mine data with the objective of identifying novel disease-modifying target genes best suited to its proprietary platform technology, as well as optimising patient stratification and UK recruitment in the development of its RNAi product candidates.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:
“We are pleased to collaborate with Genomics England both to identify novel target genes with validation in large human cohorts and to aid patient selection for our planned clinical trials. We look forward to continuing to advance our drug development efforts and to be able to better serve patients and their caregivers. This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities.”

Joanne Hackett, Chief Commercial Officer of Genomics England, commented:

“Our collaboration with Silence Therapeutics is a great example of the utility of the Genomics England platform. The Discovery Forum was established to enable innovative research that will help improve patient outcomes for NHS patients, and patients around the world. We are proud to be working with Silence Therapeutics as they continue to pioneer in the field of RNAi-based therapies.”

No Comments

Post a Comment